US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 04:14:53 Source:worldViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Travis Kelce downs whiskey shot on slice of bread at Kelce Jam without Taylor Swift
Next:Jessica Biel CHOPS her long locks into a bob after book signing in Studio City
You may also like
- Medics remove 150 MAGGOTS from a woman's mouth after dental procedure left her with rotting tissue
- US weather: Tornadoes kill 3 as forecasters warn of wave of dangerous storms
- Tiger Woods to be lone player on negotiating committee with Saudis
- Election 2024: Trump's youngest son picked as Florida delegate to RNC
- Kylie Jenner displays her VERY edgy fashion sense in cleavage
- Steve Albini dead: Legendary rock producer passes away aged 61
- Election 2024: Trump's youngest son picked as Florida delegate to RNC
- Tiger Woods to be lone player on negotiating committee with Saudis
- Pentagon vows to keep weapons moving to Ukraine as Kyiv faces a renewed assault by Russia